Sponsored Lunch Symposium
Beyond acute respiratory disease: how to demonstrate the full public health impact of influenza and its prevention
Chair: Robert Booy
Changing the paradigm: the domino effect of influenza - beyond the respiratory disease
Robert Booy - Senior Professorial Fellow at Australia's National Centre for Immunisation Research and Surveillance; Professor, The University of Sydney, Australia
Cardiovascular complications of influenza
Charlotte Warren Gash - Assoc. Prof., London School of Hygiene & Tropical Medicine, UK
Evaluating the impact of influenza vaccines on cardiovascular outcomes - an industry perspective
Rosalind Hollingsworth - Global Medical Expert Lead, Influenza, Sanofi Pasteur, Swiftwater, USA
Company Profile: For over a century, Sanofi Pasteur has been committed to protect life through vaccination. We believe in a world where no one suffers or dies from a vaccine-preventable disease. Our vaccines help protect as many as half a billion lives every year against life-threatening infectious diseases at every stage of life. With our 15,000 employees worldwide, we seek to extend the protective power of vaccination to new infectious diseases while continuously improving existing vaccines to enhance health and well-being.
Sanofi Pasteur is the world’s largest manufacturer of influenza vaccines. In 2018, we completed a production of around 200 million doses of seasonal influenza vaccine, for both Southern and Northern hemispheres, i.e. approximately 40% of influenza vaccines distributed worldwide. Sanofi Pasteur produces vaccines against seasonal influenza on five sites: Swiftwater (Pennsylvania, USA), Pearl River (Connecticut, USA), Val de Reuil (France), Ocoyoacac (Mexico) and Shenzhen (China).